Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

Autor: Pat, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Charles H, Nash, Mary K, Murray, Paul D, Richards, Mark, Gittleman, Raye, Budway, Rakhshanda Layeequr, Rahman, Pond, Kelemen, William C, Dooley, David T, Rock, Ken, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Rok vydání: 2021
Zdroj: Annals of surgical oncology.
ISSN: 1534-4681
Popis: The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR) in breast cancer patients. We report 5-year follow-up results in addition to an exploratory analysis by age and menopausal status.The observational, prospective NBRST (NCT01479101) included 954 early-stage breast cancer patients aged 18-90 years who received neoadjuvant chemotherapy and had clinical and genomic data available. Chemosensitivity and 5-year distant metastasis-free survival (DMFS) and overall survival (OS) were assessed. In a post hoc subanalysis, results were stratified by age (≤ 50 vs. 50 years) and menopausal status in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) tumors.MammaPrint and BluePrint further classified 23% of tumors to a different subtype compared with immunohistochemistry, with more precise correspondence to pCR rates. Five-year DMFS and OS were highest in MammaPrint Low Risk, Luminal A-type and HER2-type tumors, and lowest in MammaPrint High Risk, Luminal B-type and Basal-type tumors. There was no significant difference in chemosensitivity between younger and older patients with Low-Risk (2.2% vs. 3.8%; p = 0.64) or High-Risk tumors (14.5% vs. 11.5%; p = 0.42), or within each BluePrint subtype; this was similar when stratifying by menopausal status. The 5-year outcomes were comparable by age or menopausal status for each molecular subtype.Intrinsic preoperative chemosensitivity and long-term outcomes were precisely determined by BluePrint and MammaPrint regardless of patient age, supporting the utility of these assays to inform treatment and surgical decisions in early-stage breast cancer.
Databáze: OpenAIRE
Externí odkaz: